S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
NASDAQ:AXNX

Axonics - AXNX Stock Forecast, Price & News

$70.44
-0.33 (-0.47%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$70.41
$74.44
50-Day Range
$61.25
$78.12
52-Week Range
$38.41
$79.92
Volume
541,527 shs
Average Volume
651,729 shs
Market Capitalization
$3.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$77.86

Axonics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
10.5% Upside
$77.86 Price Target
Short Interest
Healthy
8.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.89
Upright™ Environmental Score
News Sentiment
1.21mentions of Axonics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$12.27 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.86) to ($1.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

214th out of 1,095 stocks

Surgical & Medical Instruments Industry

24th out of 106 stocks

AXNX stock logo

About Axonics (NASDAQ:AXNX) Stock

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

AXNX Stock News Headlines

Is This Medical Gear Maker Ready To Continue Its Rally?
Medical gear maker Axonics rallied to a new high after an announcement that it entered the Canadian market. Is it set for bigger gains on strong revenue growth?
Are Medical Stocks Lagging Axonics (AXNX) This Year?
See More Headlines
Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

AXNX Company Calendar

Last Earnings
8/01/2022
Today
10/02/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXNX
Employees
517
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$77.86
High Stock Price Forecast
$87.00
Low Stock Price Forecast
$65.00
Forecasted Upside/Downside
+10.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-80,070,000.00
Pretax Margin
-36.82%

Debt

Sales & Book Value

Annual Sales
$180.29 million
Book Value
$10.42 per share

Miscellaneous

Free Float
46,023,000
Market Cap
$3.32 billion
Optionable
Not Optionable
Beta
0.42

Key Executives

  • Mr. Raymond W. CohenMr. Raymond W. Cohen (Age 63)
    CEO & Director
    Comp: $1.34M
  • Mr. Danny L. DearenMr. Danny L. Dearen (Age 59)
    Pres & CFO
    Comp: $790.2k
  • Mr. Rinda K. SamaMr. Rinda K. Sama (Age 42)
    Chief Operating Officer
    Comp: $758.6k
  • Dr. John Woock Ph.D. (Age 38)
    Exec. VP, Chief Marketing & Strategy Officer
    Comp: $586.35k
  • Mr. Alfred J. Ford Jr.Mr. Alfred J. Ford Jr. (Age 51)
    Chief Commercial Officer
    Comp: $585.99k
  • Mr. Guangqiang Jiang Ph.D. (Age 48)
    Chief Technology Officer
  • Mr. Neil Bhalodkar
    VP of Investor Relations
  • Mr. Aaron Pettit
    Gen. Counsel & Chief Compliance Officer
  • Mr. Michael V. Williamson Esq. (Age 50)
    J.D., Sr. VP, Gen. & IP Counsel
  • Dr. Karen L. Noblett M.A.S. (Age 58)
    M.D., Chief Medical Officer













AXNX Stock - Frequently Asked Questions

Should I buy or sell Axonics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXNX shares.
View AXNX analyst ratings
or view top-rated stocks.

What is Axonics' stock price forecast for 2022?

8 Wall Street analysts have issued 12 month price targets for Axonics' stock. Their AXNX share price forecasts range from $65.00 to $87.00. On average, they anticipate the company's stock price to reach $77.86 in the next twelve months. This suggests a possible upside of 10.5% from the stock's current price.
View analysts price targets for AXNX
or view top-rated stocks among Wall Street analysts.

How have AXNX shares performed in 2022?

Axonics' stock was trading at $56.00 at the beginning of the year. Since then, AXNX shares have increased by 25.8% and is now trading at $70.44.
View the best growth stocks for 2022 here
.

When is Axonics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our AXNX earnings forecast
.

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) released its quarterly earnings data on Monday, August, 1st. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.10. The firm had revenue of $68.98 million for the quarter, compared to analysts' expectations of $60.05 million. Axonics had a negative net margin of 35.19% and a negative trailing twelve-month return on equity of 16.34%. The firm's revenue for the quarter was up 50.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.59) earnings per share.

What guidance has Axonics issued on next quarter's earnings?

Axonics updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $253.00 million-$253.00 million, compared to the consensus revenue estimate of $238.74 million.

What is Raymond W. Cohen's approval rating as Axonics' CEO?

20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include Raytheon Technologies (RTX), Honeywell International (HON), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

(AXNX) raised $100 million in an IPO on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What is Axonics' stock symbol?

Axonics trades on the NASDAQ under the ticker symbol "AXNX."

How do I buy shares of Axonics?

Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axonics' stock price today?

One share of AXNX stock can currently be purchased for approximately $70.44.

How much money does Axonics make?

Axonics (NASDAQ:AXNX) has a market capitalization of $3.32 billion and generates $180.29 million in revenue each year. The company earns $-80,070,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

How many employees does Axonics have?

The company employs 517 workers across the globe.

How can I contact Axonics?

Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The official website for the company is www.axonics.com. The company can be reached via phone at (866) 722-5738, via email at ir@axonics.com, or via fax at 949-396-6321.

This page (NASDAQ:AXNX) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.